AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average, and it is also part of the Nasdaq-100 Index, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.THOUSAND OAKS, Calif., Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
加利福尼亞千橡市，2024年11月8日 /美通社/ -- 安進（納斯達克:AMGN）將於2024年11月13日星期三上午10:15出席2024年UBS全球醫療保健大會。安進的首席財務官彼得·格里菲斯將在會議上發表演講。網絡研討會將同時通過互聯網進行廣播，並向新聞媒體、投資者和普通公衆開放。
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
網上直播將在安進公司網站的投資者關係頁面中提供，與其他關於安進業務的一些演講一樣，詳細信息可以在安進公司網站的投資者關係事件日曆中得到。網上直播將被保存並可供回放至少90天。
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
關於安進
安進發現，開發，製造和提供創新藥物，以幫助數百萬患者對抗世界上最嚴峻的疾病。 40多年前，安進幫助建立了生物技術行業，並始終處於創新的前沿，利用技術和人類基因數據推動超越當今已知的領域。 安進正在推進一個廣泛而深入的流水線，該流水線建立在其現有藥物組合的基礎上，用於治療癌症，心臟病，骨質疏鬆症，炎症性疾病和罕見疾病。
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average, and it is also part of the Nasdaq-100 Index, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
在2024年，Amgen被Fast Company評爲「全球最具創新力的公司」之一，並被福布斯評選爲「美國最佳大型僱主」等其他外部認可。 Amgen是由30家公司組成的道瓊斯工業平均指數的成員之一，也是納斯達克100指數的一部分，該指數包括納斯達克證券市場上按市值排序的最大和最具創新力的非金融公司。
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads.
欲知更多信息，請訪問安進公司網站並在X、LinkedIn、Instagram、TikTok、YouTube和Threads上關注安進。
CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
聯繫方式：安進，Thousands Oaks
Elissa Snook，609-251-1407（媒體）
Justin Claeys, 805-313-9775（投資者聯繫人）
SOURCE Amgen
信息來源：安進
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
